Mispro Announces Tenth Boston Location in Cambridge, MA

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 9, 2024--

Mispro, a leading contract vivarium organization (CVO), has announced that its newest Metro-Boston facility will open this December on Binney Street in Kendall Square, Cambridge, MA.

Strategically positioned in the heart of Kendall Square, a globally recognized hub for biotechnology and pharmaceutical innovation, Mispro’s Binney Street facility will offer turnkey vivarium lab space and comprehensive support services for preclinical in vivo studies. This expansion is part of Mispro’s broader strategy to maintain proximity to its clients, enabling them to access critical resources and collaborate within one of the most dynamic biotech ecosystems in the world.

“Our location-centric strategy is driven by the need to be where innovation happens,” said Philippe Lamarre, CEO of Mispro. “By expanding our footprint in Kendall Square, we are ensuring that neighboring biotech companies, both large and small, have the infrastructure they need to effectively advance their preclinical research. Mispro’s proximity to world-class academic institutions, pharma companies, and biotech incubators is not just convenient; it’s a key strategic advantage that enables direct hands-on oversight and accelerates innovation.”

Mispro’s state-of-the-art facilities provide biosciences companies with access to cutting-edge lab environments, supported by expert husbandry, veterinary care, and regulatory compliance oversight. This enables researchers to focus on their scientific objectives and keep research in-house, while Mispro manages the operational complexities of building, managing, and staffing a vivarium.

“Working in Mispro’s facility has been a very effective choice for KalVista,” said Allen Clermont, Director of Preclinical Pharmacology at KalVista Pharmaceuticals. “They give us the space and support we need to be able to focus on hitting milestones with valid data sets that we’ve been able to reproduce in later stage trials.”

In today’s competitive biotech market, effective allocation of resources is more critical than ever. With increasing pressure on funding and timelines, many companies are re-evaluating how they invest in infrastructure. Mispro’s contract vivarium model offers a cost-effective solution that allows companies to allocate their resources where they matter most—on rapidly advancing their therapeutic programs.

“Partnering with Mispro is a smart strategy in today’s financial climate,” added Lamarre. “By leveraging our facilities and expertise, biotech companies can optimize their spending, reduce risk, and accelerate the pace of their research. This model empowers them to focus on what truly matters—developing groundbreaking therapies.”

The new Binney Street facility will add significant capacity to Mispro’s existing network, which already includes two other facilities in Kendall Square, bringing the total to ten in the Metro-Boston area. With this expansion, Mispro continues to lead the way in providing essential infrastructure for the next generation of biotech innovation.

About Mispro:Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium lab facilities for preclinical in vivo studies. Along with access to state-of-the-art turnkey lab space, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

View source version on businesswire.com:https://www.businesswire.com/news/home/20240909542492/en/

CONTACT: Media Contact:

John Fogarty

Director of Marketing

jfogarty@mispro.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: OTHER HEALTH RESEARCH PHARMACEUTICAL DATA MANAGEMENT TECHNOLOGY HEALTH TECHNOLOGY CLINICAL TRIALS SCIENCE VETERINARY BIOTECHNOLOGY OTHER SCIENCE HEALTH

SOURCE: Mispro

Copyright Business Wire 2024.